Recursion Pharmaceuticals, Inc. - Class A Common Stock
Recursion Pharmaceuticals, Inc. - Class A Common Stock
Share · US75629V1044 · RXRX (XNAS)
Overview Financial Indicators
5,57 USD
23,23 % 1,05 USD
NASDAQ (XNAS) · Current prices and charts at MoneyPeak
06.06.2025 23:59

Current Prices from Recursion Pharmaceuticals, Inc. - Class A Common Stock

ExchangeTickerCurrencyLast TradePriceDaily Change
XNAS: NASDAQ
NASDAQ
RXRX
USD
06.06.2025 23:59
5,57 USD
4,56 USD
+22,14 %

Performance

Day Week Month 3 Months 6 Months 1 Year 5 Years
0,00 % 32,62 % 33,25 % -15,48 % -30,38 % -34,55 % -69,06 %

Company Profile for Recursion Pharmaceuticals, Inc. - Class A Common Stock Share

Recursion Pharmaceuticals, Inc. operates as a clinical-stage biotechnology company, engages in the decoding biology by integrating technological innovations across biology, chemistry, automation, data science, and engineering to industrialize drug discovery. The company develops REC-994, which is in Phase IIa clinical trial to treat cerebral cavernous malformation; REC-2282 for the treatment of neurofibromatosis type 2; REC-4881 to treat familial adenomatous polyposis; and REC-3599, which is in Phase I clinical trial to treat GM2 gangliosidosis. Its preclinical stage product includes REC-3964 to treat Clostridium difficile colitis; REC-64917 for the treat of neural or systemic inflammation; REC-65029 to treat HRD-negative ovarian cancer; REC-648918 to enhance anti-tumor immune; REC-2029 for the treatment of wnt-mutant hepatocellular carcinoma; REC-14221 to treat solid and hematological malignancies; and REC-64151 for the treatment of immune checkpoint resistance in KRAS/STK11 mutant non-small cell lung cancer. The company has collaboration and agreement with Bayer AG; the University of Utah Research Foundation; Ohio State Innovation Foundation; Chromaderm, Inc.; and Takeda Pharmaceutical Company Limited. Recursion Pharmaceuticals, Inc. was incorporated in 2013 and is headquartered in Salt Lake City, Utah.

Company Data

Name Recursion Pharmaceuticals, Inc. - Class A Common Stock
Company Recursion Pharmaceuticals, Inc.
Symbol RXRX
Website https://www.recursion.com
Primary Exchange XNAS NASDAQ
ISIN US75629V1044
Asset Class Share
Sector Healthcare
Industry Biotechnology
CEO Dr. Christopher C. Gibson Ph.D.
Market Capitalization 2 Mrd.
Country United States of America
Currency USD
Employees 0,8 T
Address 41 South Rio Grande Street, 84101 Salt Lake City
IPO Date 2021-04-16

Ticker Symbols

Name Symbol
NASDAQ RXRX

More Shares

Investors who Recursion Pharmaceuticals, Inc. - Class A Common Stock hold also have the following shares in their portfolio:
BlackRock ETF Trust BlackRock Future Financial and Technology ETF
BlackRock ETF Trust BlackRock Future Financial and Technology ETF ETF
VMED 02 UK I 20/31 REGS
VMED 02 UK I 20/31 REGS Bond
The financial platform MoneyPeak tracks and analyzes investments and portfolios. From securities portfolios to crypto purchases.
Useful, simple, and free. Stocks, ETFs, ETCs, ETNs, indices, funds, bonds, certificates, currencies, options, rights issue.
Imprint Data Protection Blog Community Feedback Changelog
Im App Store herunterladen Bei Google Play herunterladen
All rights reserved © LCP GmbH 2025